Allurion stock soars on weight-loss therapy update. Stardust Power breaks ground on Oklahoma lithium refinery. OpenAI ...

Novo Nordisk’s NVO amycretin, which targets GLP-1 and amylin in one molecule, generated 24% placebo-adjusted weight loss in a ...

Early research suggests GLP-1 drugs could prevent or treat Alzheimer's Disease. Results from a big clinical trial could soon ...

The author of a new guidebook on GLP-1s and other experts share their tips for how clinicians can optimize patient success ...

About one in eight adults in the United States has tried or currently uses a GLP-1 medication, and a quarter of those users ...

GLP-1 agonist initiators had a significantly higher likelihood of undergoing thyroid ultrasonography at 6 and 12 months, ...

Diabetes and weight management drugs dominated game-day NFL advertising during the regular season, with TV outcomes company ...

Oprah Winfrey reflects on past misconceptions about weight, admitting that a GLP-1 drug shifted her perspective.

If you're one of the 13% of American adults who has taken a GLP-1 drug for weight loss, you may know that while fat seemingly ...

A novel GLP-1 and amylin receptor agonist featured a safety profile similar to other incretin-based therapies and conferred a ...

About one in eight adults in the United States has tried or currently uses a GLP-1 medication, and a quarter of those users ...

The disease afflicts nearly seven million Americans, about one in every nine people over the age of 65, making it a leading ...